Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury
63% of treated animals achieved at least five points of motor function improvement versus 11.5% of controls, representing an approximately 5.5 times higher responder rateStatistically significant motor function benefits demonstrated in both sexes at every assessment from Week 9 through Week 12Ness Ziona, Israel--(Newsfile Corp. - November 5, 2026) - Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized engineered neural tissue for spinal cord injury, today announced...
Free plan · Plus CA$29 or Pro CA$99/month


